Novel approach in monocyte intracellular TNF measurement: Application to sepsis-induced immune alterations

Shock

Volumn 47, Issue 3, 2017, Pages 318-322

  Monneret, Guillaume ^a,b,c   Demaret, Julie ^a,b   Gossez, Morgane ^a,b   Reverdiau, Elsa ^a   Malergue, Fabrice ^d   Rimmelé, Thomas ^a,b   Venet, Fabienne ^a,b  

^a EDOUARD HERRIOT HOSPITAL   (France)

^b University of Lyon EA 7426 Pathophysiology of Injury Induced Immunosuppression PI3   (France)

^c TRIGGERSEP (TRIal Group for Global Evaluation and Research in SEPsis)   (France)

^d Immunotech   (France)

Author keywords

HLA DR; immunosuppression; monocyte; sepsis; septic shock; tumor necrosis factor

Indexed keywords

HLA DR ANTIGEN; LIPOPOLYSACCHARIDE; TUMOR NECROSIS FACTOR; IMMUNOLOGICAL ADJUVANT;

ARTICLE; CD4 LYMPHOCYTE COUNT; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION COEFFICIENT; FEASIBILITY STUDY; FLOW CYTOMETRY; FLUORESCENCE; HOSPITAL INFECTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; IN VITRO STUDY; INTENSIVE CARE UNIT; MONOCYTE; OBSERVATIONAL STUDY; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; SEPTIC SHOCK; AGED; BLOOD; FEMALE; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; MALE; METABOLISM; MIDDLE AGED; SEPSIS;

ADJUVANTS, IMMUNOLOGIC; AGED; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNE TOLERANCE; LIPOPOLYSACCHARIDES; MALE; MIDDLE AGED; MONOCYTES; SEPSIS; SHOCK, SEPTIC; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84981526534     PISSN: 10732322     EISSN: 15400514     Source Type: Journal    
DOI: 10.1097/SHK.0000000000000724     Document Type: Article

References (28)

1. Deutschman CS, Tracey KJ: Sepsis: current dogma and new perspectives. Immunity 40:463-475, 2014.
2. Angus DC, van der Poll T: Severe sepsis and septic shock. N Engl J Med 369:840-851, 2013.
3. Hotchkiss RS, Monneret G, Payen D: Sepsis-induced immunosuppression: from cellular dysfunctions to immunotherapy. Nat Rev Immunol 13:862-874, 2013.
4. Torgersen C, Moser P, Luckner G, Mayr V, Jochberger S, Hasibeder WR, Dunser MW: Macroscopic postmortem findings in 235 surgical intensive care patients with sepsis. Anesth Analg 108:1841-1847, 2009.
5. Boomer JS, To K, Chang KC, Takasu O, Osborne DF, Walton AH, Bricker TL, Jarman SD 2nd, Kreisel D, Krupnick AS, et al.: Immunosuppression in patientswho die of sepsis andmultiple organ failure. JAMA306:2594-2605, 2011.
6. van Vught LA, Klein Klouwenberg PM, Spitoni C, Scicluna BP, Wiewel MA, Horn J, Schultz MJ, Nurnberg P, Bonten MJ, Cremer OL, et al.: Incidence, risk factors, and attributable mortality of secondary infections in the intensive care unit after admission for sepsis. JAMA 315:1469-1479, 2016.
7. Otto GP, Sossdorf M, Claus RA, Rodel J, Menge K, Reinhart K, Bauer M, Riedemann NC: The late phase of sepsis is characterized by an increased microbiological burden and death rate. Crit Care 15:R183, 2011.
8. Daviaud F, Grimaldi D, Dechartres A, Charpentier J, Geri G, Marin N, Chiche JD, Cariou A, Mira JP, Pene F: Timing and causes of death in septic shock. Ann Intensive Care 5:58, 2015.
9. Hotchkiss RS, Monneret G, Payen D: Immunosuppression in sepsis: a novel understanding of the disorder and a new therapeutic approach. Lancet Infect Dis 13:260-268, 2013.
10. Monneret G, Venet F: Sepsis-induced immune alterations monitoring by flow cytometry as a promising tool for individualized therapy. Cytometry B Clin Cytom 90:376-386, 2016.
11. Venet F, Lukaszewicz AC, Payen D, Hotchkiss R, Monneret G: Monitoring the immune response in sepsis: a rational approach to administration of immunoadjuvant therapies. Curr Opin Immunol 25:477-483, 2013.
12. Monneret G, Venet F: Immune functional testing in clinics: feasibility and prediction of deleterious outcomes. Crit Care Med 41:367-368, 2013.
13. Biswas SK, Lopez-Collazo E: Endotoxin tolerance: new mechanisms, molecules and clinical significance. Trends Immunol 30:475-487, 2009.
14. van Vught LA,Wiewel MA, Hoogendijk AJ, Scicluna BP, Belkasim-Bohoudi H, Horn J, Schultz MJ, van der Poll T: Reduced responsiveness of blood leukocytes to lipopolysaccharide does not predict nosocomial infections in critically ill patients. Shock 44:110-114, 2015.
15. Freer G, Rindi L: Intracellular cytokine detection by fluorescence-activated flow cytometry: basic principles and recent advances. Methods 61:30-38, 2013.
16. Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, Schein RM, Sibbald WJ: Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 101:1644-1655, 1992.
17. Docke WD, Hoflich C, Davis KA, Rottgers K, Meisel C, Kiefer P, Weber SU, Hedwig-GeissingM,Kreuzfelder E, Tschentscher P, et al.:Monitoring temporary immunodepression by flow cytometric measurement of monocytic HLADR expression: a multicenter standardized study. Clin Chem 51:2341-2347, 2005.
18. Opal SM: The current understanding of sepsis and research priorities for the future. Virulence 5:1-3, 2014.
19. Monneret G, Venet F, Pachot A, Lepape A: Monitoring immune dysfunctions in the septic patient: a new skin for the old ceremony. Mol Med 14:64-78, 2008.
20. Cavaillon JM, Adib-Conquy M: Bench-to-bedside review: endotoxin tolerance as a model of leukocyte reprogramming in sepsis. Crit Care 10:233, 2006.
21. Segre E, Fullerton JN: Stimulated whole blood cytokine release as a biomarker of immunosuppression in the critically ill: the need for a standardized methodology. Shock 45:490-494, 2016.
22. Fumeaux T, Dufour J, Stern S, Pugin J: Immune monitoring of patients with septic shock by measurement of intraleukocyte cytokines. Intensive Care Med 30:2028-2037, 2004.
23. Pala P, Hussell T, Openshaw PJ: Flow cytometric measurement of intracellular cytokines. J Immunol Methods 243:107-124, 2000.
24. Demaret J, Saison J, Venet F, Malcus C, Poitevin-Later F, Lepape A, Ferry T, Monneret G: Assessment of a novel flow cytometry technique of one-step intracellular staining: example of FOXP3 in clinical samples. Cytometry B Clin Cytom 84:187-193, 2013.
25. Dupont G, Demaret J, Venet F, Malergue F, Malcus C, Poitevin-Later F, Morel J, Monneret G: Comparative dose-responses of recombinant human IL-2 and IL-7 on STAT5 phosphorylation in CD4+FOXP3-cells versus regulatory T cells: a whole blood perspective. Cytokine 69:146-149, 2014.
26. Demaret J, Dupont G, Venet F, Friggeri A, Lepape A, Rimmele T, Morel J, Monneret G: STAT5 phosphorylation in T cell subsets from septic patients in response to recombinant human interleukin-7: a pilot study. J Leukoc Biol 97:791-796, 2015.
27. Hall MW, Knatz NL, Vetterly C, Tomarello S, Wewers MD, Volk HD, Carcillo JA: Immunoparalysis and nosocomial infection in children with multiple organ dysfunction syndrome. Intensive Care Med 37:525-532, 2011.
28. Meisel C, Schefold JC, Pschowski R, Baumann T, Hetzger K, Gregor J, Weber-Carstens S, Hasper D, Keh D, Zuckermann H, et al.: Granulocyte-macrophage colony-stimulating factor to reverse sepsis-associated immunosuppression: a double-blind, randomized, placebo-controlled multicenter trial. Am J Respir Crit Care Med 180:640-648, 2009.